REGULATORY

• Deregulation Panel Pushes PMDA to Digitalize Process
  June 6, 2018

• Reward Innovation to Solve Social Challenges: LDP Study Group
  June 6, 2018

• Japan Eyes Economic Assessments for New Drug Listing: Draft Honebuto Paper
  June 6, 2018

• Large Vessel Vasculitis to Be Added to Significant Adverse Reactions for G-CSF Preparations: MHLW
  June 6, 2018

• Invoice Price Rates Decline Only for Long-listed Drugs at 3 Companies: MHLW Survey
  June 4, 2018

• “Preclinical Registry” Will Accelerate Drug Discovery in Field of Dementia: AMED President
  June 4, 2018

• AMED to Increase Transparency in Funding by Opening Up Research Database to Public
  June 1, 2018

• Ex-Minister Shiozaki Holds Talks with PhRMA, EFPIA
  June 1, 2018

• MHLW to End Manufacturing Record Inspection for Kaketsuken’s Plasma Fraction Products
  June 1, 2018

• MHLW Positive on Enshrining Conditional Approval, Sakigake Schemes into Law: Official
  May 31, 2018

• Japan’s First Biosimilars for Enbrel, Herceptin Added to NHI Price List
  May 30, 2018

• Honebuto Policy Won’t Include Numerical Target for Social Security Costs
  May 29, 2018

• Takeda’s Entyvio Up for MHLW Panel Review on June 8
  May 28, 2018

• MHLW Grants Orphan Status to Vyndaqel, Burosumab
  May 28, 2018

• MHLW OKs Add’l Indications for Xeljanz, Botox, Nucala
  May 28, 2018

• MOF Pitching 2-Step Drug Price Tweaks in 2019 Tax Hike Year
  May 25, 2018

• MHLW Flu Panel Approves Plan to Switch to H7N9 Strain for Pre-Pandemic Flu Vaccine
  May 25, 2018

• Chuikyo Approves Insurance Reimbursement for 3 Medical Devices, with Listing Scheduled for June
  May 25, 2018

• Chuikyo Tightens Physician Fee Rules for Self-Injections, Biosimilars Up for Individual Review
  May 25, 2018

• Lynparza’s Breast Cancer Use, Chugai’s Obinutuzumab Clear MHLW Panel
  May 24, 2018

ページ

• « 先頭
• ‹ Prev
• …
• 222
• 223
• 224
• 225
• 226
• 227
• 228
• 229
• 230
• …
• Next ›
• 最終 »